ClinicalTrials.gg
CompletedNCT03859700EPOPEXUpdated Oct 28, 2026Results posted

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

A Phase 3 interventional study of DBV712 250 mcg in Peanut Allergy, sponsored by DBV Technologies. Completed at 26 sites in United States. Open to participants aged 2 Years to 5 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by DBV Technologies · Phase 3, Interventional, and Treatment

Updated Oct 28, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
304
Allocation
Not applicable
Ages
2 Years to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing palforzia in Peanut Hypersensitivity — none open to participants now, 3 under way, 2 of them phase 3. Palforzia · Peanut Hypersensitivity.

Enrollment
4th of 10
304 · median 105
Started
2018
the only one that year
Phase 3
4 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
5 of 10
DBV Technologies

Among the 10 studies testing palforzia in Peanut Hypersensitivity, this one is the 4th largest by enrollment, is the only one that started in 2018, is one of 4 in phase 3, and was the 6th registered.

Peanut Hypersensitivity

166 studies on the registry are indexed under Peanut Hypersensitivity; 27 are open to participants now.

Browse Peanut Hypersensitivity studies →

Open to participants now

None of the 10 studies testing palforzia in Peanut Hypersensitivity is open now. The open studies under Peanut Hypersensitivity, anywhere →

About palforzia

Palforzia: first FDA approval 2020 (Palforzia). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Peanut Hypersensitivity studies recruiting now, 2 (11%) set no upper age limit and 16 (89%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.

This study: 2 Years to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing palforzia in Peanut Hypersensitivity as a file.
02

Study summary

Open-label, follow-up study for subjects who completed the EPITOPE study.

03

Conditions studied

  • Peanut Allergy

Keywords

  • EPIT
  • Epicutaneous
  • Immunotherapy
  • Viaskin
04

Who can participate

Ages eligible
2 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • completion of the EPITOPE study

Exclusion criteria

Exclusion Criteria:

  • Generalized dermatologic disease (for example, active atopic dermatitis, uncontrolled generalized active eczema, ichthyosis vulgaris) extending widely on the skin and especially on the back or arms with no intact zones to apply the Viaskin patches.
  • Diagnosis of asthma that evolved to severe, unstable or uncontrolled asthma
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
304 participants (actual)

Study arms

  • Experimental
    DBV712 250mcg

    DBV712 250 mcg, once daily

    Biological: DBV712 250 mcg

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Were Treatment Responders at Months 12, 24, 36 and 48

    A participant was defined as treatment responder if: * The V712-304 (EPITOPE) baseline ED was \>10 mg peanut protein and the ED was ≥1000 mg peanut protein at the post-baseline DBPCFCs or; * The V712-304 (EPITOPE) baseline ED was ≤10 mg and the ED is ≥300 mg peanut protein at the post-baseline DBPCFCs. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).

    Time frame: Months 12, 24, 36 and 48

Other outcomes

  1. Percentage of Participants Reaching an ED ≥ 2000 mg Peanut Protein at Months 12, 24, 36 and 48

    ED was defined, at every DBPCFC, as the peanut protein dose that triggered any dose-limiting symptom, defined by standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).

    Time frame: Months 12, 24, 36 and 48

  2. Percentage of Participants Who Tolerated ≥ 1000 mg Peanut Protein at Months 12, 24, 36 and 48

    Tolerated Dose (TD) was defined, at every DBPCFC, as the maximum single peanut protein dose that was associated with no or mild (not dose limiting) symptoms, based upon standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).

    Time frame: Months 12, 24, 36 and 48

  3. Percentage of Participants Who Tolerated ≥ 2000 mg Peanut Protein at Months 12, 24, 36 and 48

    Tolerated Dose (TD) was defined, at every DBPCFC, as the maximum single peanut protein dose that was associated with no or mild (not dose limiting) symptoms, based upon standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).

    Time frame: Months 12, 24, 36 and 48

  4. Tolerated Doses of Peanut Protein at Baseline and Months 12, 24, 36 and 48

    Tolerated Dose (TD) was defined, at every DBPCFC, as the maximum single peanut protein dose that was associated with no or mild (not dose limiting) symptoms, based upon standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).

    Time frame: Baseline and Months 12, 24, 36 and 48

  5. EDs of Peanut Protein at Baseline and Months 12, 24, 36 and 48

    ED was defined, at every DBPCFC, as the peanut protein dose that triggered any dose-limiting symptom, defined by standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).

    Time frame: Baseline and Months 12, 24, 36 and 48

  6. Cumulative Reactive Doses (CRD) of Peanut Protein at Baseline and Months 12, 24, 36 and 48

    CDR was defined, at every DBPCFC, as the sum of all the doses consumed (in mg) of food protein, including the eliciting dose. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).

    Time frame: Baseline and Months 12, 24, 36 and 48

  7. Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs), and AEs of Special Interest (AESI)

    TEAEs: any AE occurring at first EPOPEX VP patch application or pre-existing but worsening in either severity or relationship to the IMP following initial exposure to VP patch in EPOPEX trial. Clinically significant changes in vital signs, physical exams, or labs after first IMP were considered TEAEs. SAE: any event resulting in death, life-threatening condition, hospitalization or its prolongation, significant or persistent disability, congenital anomaly or birth defect, or any important medical event that may not be immediately life-threatening but could jeopardize the participant or require intervention to prevent such outcomes. AESI: local (any patch-site reaction that could disrupt the skin barrier) and systemic (immediate systemic allergic reaction after exposure to a known/suspected allergen, including anaphylaxis or hypersensitivity requiring epinephrine, outside DBPCFCs). AEs from accidental peanut intake and SAEs related to DBPCFC were excluded.

    Time frame: During 36 months of active treatment

  8. Number of Participants Who Experienced SAEs During DBPCFC After Peanut Formula at Months 12, 24, 36 and 48

    A SAE was defined as any untoward medical occurrence that at any dose: resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability or incapacity; was a congenital anomaly or birth defect; was an important medical event that may not be immediately life-threatening or result in death or hospitalization but that may jeopardize the participant or require intervention to prevent one of the above outcomes. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).

    Time frame: Months 12, 24, 36 and 48

  9. Percentage of Participants Reaching an Eliciting Dose (ED) ≥ 1000 mg Peanut Protein at Months 12, 24, 36 and 48

    ED was defined, at every DBPCFC, as the peanut protein dose that triggered any dose-limiting symptom, defined by standardized criteria. DBPCFC occurred at baseline and at every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12)

    Time frame: 12, 24, 36, 48 months

07

Results

Posted Oct 28, 2026

Participant flow

Participant flow — Overall Study
MilestoneDBV712 250mcg+DBV712 250mcgPlacebo+DBV712 250mcg
Started20599
Completed14456
Not completed6143
Withdrew: Withdrawal by subject4733
Withdrew: Physician decision41
Withdrew: Adverse event22
Withdrew: Miscellaneous52
Withdrew: Lost to follow-up32
Withdrew: Protocol violation02
Withdrew: Non-compliance with study drug01

Outcome measures

PrimaryPercentage of Participants Who Were Treatment Responders at Months 12, 24, 36 and 48

A participant was defined as treatment responder if: * The V712-304 (EPITOPE) baseline ED was \>10 mg peanut protein and the ED was ≥1000 mg peanut protein at the post-baseline DBPCFCs or; * The V712-304 (EPITOPE) baseline ED was ≤10 mg and the ED is ≥300 mg peanut protein at the post-baseline DBPCFCs. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).

Time frame:
Months 12, 24, 36 and 48
Reported as:
Count of participants · Participants
Percentage of Participants Who Were Treatment Responders at Months 12, 24, 36 and 48
ParticipantsDBV712 250mcg+DBV712 250mcgPlacebo+DBV712 250mcg
Month 1215438
Month 2415955
Month 3614048
Month 48—39
Other pre-specifiedPercentage of Participants Reaching an ED ≥ 2000 mg Peanut Protein at Months 12, 24, 36 and 48

ED was defined, at every DBPCFC, as the peanut protein dose that triggered any dose-limiting symptom, defined by standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).

Time frame:
Months 12, 24, 36 and 48
Reported as:
Count of participants · Participants
Percentage of Participants Reaching an ED ≥ 2000 mg Peanut Protein at Months 12, 24, 36 and 48
ParticipantsDBV712 250mcg+DBV712 250mcgPlacebo+DBV712 250mcg
Month 129613
Month 2411129
Month 3610927
Month 48—24
Other pre-specifiedPercentage of Participants Who Tolerated ≥ 1000 mg Peanut Protein at Months 12, 24, 36 and 48

Tolerated Dose (TD) was defined, at every DBPCFC, as the maximum single peanut protein dose that was associated with no or mild (not dose limiting) symptoms, based upon standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).

Time frame:
Months 12, 24, 36 and 48
Reported as:
Count of participants · Participants
Percentage of Participants Who Tolerated ≥ 1000 mg Peanut Protein at Months 12, 24, 36 and 48
ParticipantsDBV712 250mcg+DBV712 250mcgPlacebo+DBV712 250mcg
Month 1210718
Month 2413536
Month 3612033
Month 48—27
Other pre-specifiedPercentage of Participants Who Tolerated ≥ 2000 mg Peanut Protein at Months 12, 24, 36 and 48

Tolerated Dose (TD) was defined, at every DBPCFC, as the maximum single peanut protein dose that was associated with no or mild (not dose limiting) symptoms, based upon standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).

Time frame:
Months 12, 24, 36 and 48
Reported as:
Count of participants · Participants
Percentage of Participants Who Tolerated ≥ 2000 mg Peanut Protein at Months 12, 24, 36 and 48
ParticipantsDBV712 250mcg+DBV712 250mcgPlacebo+DBV712 250mcg
Month 12687
Month 249623
Month 3610323
Month 48—22
Other pre-specifiedTolerated Doses of Peanut Protein at Baseline and Months 12, 24, 36 and 48

Tolerated Dose (TD) was defined, at every DBPCFC, as the maximum single peanut protein dose that was associated with no or mild (not dose limiting) symptoms, based upon standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).

Time frame:
Baseline and Months 12, 24, 36 and 48
Reported as:
Mean · mg
Tolerated Doses of Peanut Protein at Baseline and Months 12, 24, 36 and 48
mgDBV712 250mcg+DBV712 250mcgPlacebo+DBV712 250mcg
Baseline51.4 ± 42.1561.7 ± 41.39
Month 12949.9 ± 816.95343.2 ± 549.30
Month 241289.2 ± 811.85841.9 ± 811.59
Month 361396.6 ± 803.78898.6 ± 866.91
Month 48—937.9 ± 879.39
Other pre-specifiedEDs of Peanut Protein at Baseline and Months 12, 24, 36 and 48

ED was defined, at every DBPCFC, as the peanut protein dose that triggered any dose-limiting symptom, defined by standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).

Time frame:
Baseline and Months 12, 24, 36 and 48
Reported as:
Mean · mg
EDs of Peanut Protein at Baseline and Months 12, 24, 36 and 48
mgDBV712 250mcg+DBV712 250mcgPlacebo+DBV712 250mcg
Baseline152.9 ± 123.9176.9 ± 121.27
Month 121264.5 ± 766.39592.1 ± 657.18
Month 241110.7 ± 752.76419.0 ± 648.12
Month 361424.0 ± 684.35989.3 ± 797.85
Month 48—1230.8 ± 779.69
Other pre-specifiedCumulative Reactive Doses (CRD) of Peanut Protein at Baseline and Months 12, 24, 36 and 48

CDR was defined, at every DBPCFC, as the sum of all the doses consumed (in mg) of food protein, including the eliciting dose. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).

Time frame:
Baseline and Months 12, 24, 36 and 48
Reported as:
Mean · mg
Cumulative Reactive Doses (CRD) of Peanut Protein at Baseline and Months 12, 24, 36 and 48
mgDBV712 250mcg+DBV712 250mcgPlacebo+DBV712 250mcg
Baseline224.0 ± 182.63260.0 ± 176.23
Month 122078.7 ± 1352.78918.9 ± 1094.03
Month 242512.1 ± 1255.181813.2 ± 1355.79
Month 362678.6 ± 1233.021892.4 ± 1399.94
Month 48—2033.3 ± 1381.11
Other pre-specifiedNumber of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs), and AEs of Special Interest (AESI)

TEAEs: any AE occurring at first EPOPEX VP patch application or pre-existing but worsening in either severity or relationship to the IMP following initial exposure to VP patch in EPOPEX trial. Clinically significant changes in vital signs, physical exams, or labs after first IMP were considered TEAEs. SAE: any event resulting in death, life-threatening condition, hospitalization or its prolongation, significant or persistent disability, congenital anomaly or birth defect, or any important medical event that may not be immediately life-threatening but could jeopardize the participant or require intervention to prevent such outcomes. AESI: local (any patch-site reaction that could disrupt the skin barrier) and systemic (immediate systemic allergic reaction after exposure to a known/suspected allergen, including anaphylaxis or hypersensitivity requiring epinephrine, outside DBPCFCs). AEs from accidental peanut intake and SAEs related to DBPCFC were excluded.

Time frame:
During 36 months of active treatment
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs), and AEs of Special Interest (AESI)
ParticipantsDBV712 250mcg+DBV712 250mcgPlacebo+DBV712 250mcg
TEAEs (total)20599
TEAEs related to IP20599
SAEs (total)2611
SAEs related to IP11
Local AESI6021
Systemic AESI4012
Other pre-specifiedNumber of Participants Who Experienced SAEs During DBPCFC After Peanut Formula at Months 12, 24, 36 and 48

A SAE was defined as any untoward medical occurrence that at any dose: resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability or incapacity; was a congenital anomaly or birth defect; was an important medical event that may not be immediately life-threatening or result in death or hospitalization but that may jeopardize the participant or require intervention to prevent one of the above outcomes. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).

Time frame:
Months 12, 24, 36 and 48
Reported as:
Count of participants · Participants
Number of Participants Who Experienced SAEs During DBPCFC After Peanut Formula at Months 12, 24, 36 and 48
ParticipantsDBV712 250mcg+DBV712 250mcgPlacebo+DBV712 250mcg
Month 1235
Month 2412
Month 3601
Month 48—0
Other pre-specifiedPercentage of Participants Reaching an Eliciting Dose (ED) ≥ 1000 mg Peanut Protein at Months 12, 24, 36 and 48

ED was defined, at every DBPCFC, as the peanut protein dose that triggered any dose-limiting symptom, defined by standardized criteria. DBPCFC occurred at baseline and at every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12)

Time frame:
12, 24, 36, 48 months
Reported as:
Count of participants · Participants
Percentage of Participants Reaching an Eliciting Dose (ED) ≥ 1000 mg Peanut Protein at Months 12, 24, 36 and 48
ParticipantsDBV712 250mcg+DBV712 250mcgPlacebo+DBV712 250mcg
Month 1214734
Month 2415351
Month 3613743
Month 48—39

Adverse events

Collected over Up to 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DBV712 250mcg+DBV712 250mcg0/205 (0%)26/205 (12.7%)205/205 (100%)
Placebo+DBV712 250mcg0/99 (0%)11/99 (11.1%)99/99 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventDBV712 250mcg+DBV712 250mcgPlacebo+DBV712 250mcg
AsthmaRespiratory, thoracic and mediastinal disorders1/2054/99
Anaphylactic ReactionImmune system disorders5/2053/99
WheezingRespiratory, thoracic and mediastinal disorders6/2050/99
Gastroenteritis ViralInfections and infestations1/2051/99
Viral InfectionInfections and infestations1/2051/99
OsteomyelitisInfections and infestations0/2051/99
ThrombocytopeniaBlood and lymphatic system disorders0/2051/99
Bronchial hyperreactivityRespiratory, thoracic and mediastinal disorders2/2050/99
Medication ErrorInjury, poisoning and procedural complications2/2050/99
Food AllergyImmune system disorders1/2050/99
Most frequent other events
Showing 10 of 81
Most frequent other events
EventDBV712 250mcg+DBV712 250mcgPlacebo+DBV712 250mcg
Application Site ErythemaGeneral disorders202/20597/99
Application Site PruritisGeneral disorders196/20593/99
Application Site SwellingGeneral disorders152/20565/99
PyrexiaGeneral disorders92/20559/99
Upper Resperatory tract infectionInfections and infestations116/20550/99
UrticariaSkin and subcutaneous tissue disorders98/20553/99
EczemaSkin and subcutaneous tissue disorders72/20542/99
VomitingGastrointestinal disorders73/20533/99
Corona Virus InfectionInfections and infestations43/20534/99
Viral InfectionInfections and infestations63/20532/99

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)DBV712 250mcg+DBV712 250mcgPlacebo+DBV712 250mcgTotal
<=18 years20599304
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)DBV712 250mcg+DBV712 250mcgPlacebo+DBV712 250mcgTotal
Mean2.6 ± 0.862.5 ± 0.862.5 ± 0.86
Sex: Female, Male
Sex: Female, Male(Participants)DBV712 250mcg+DBV712 250mcgPlacebo+DBV712 250mcgTotal
Female682896
Male13771208
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DBV712 250mcg+DBV712 250mcgPlacebo+DBV712 250mcgTotal
White14059199
Asian331952
Black or African American000
Other291544
Not collected369
Region of Enrollment
Region of Enrollment(participants)DBV712 250mcg+DBV712 250mcgPlacebo+DBV712 250mcgTotal
United States12361184
United Kingdom21930
Australia351449
Canada9413
France022
Germany336
Ireland11314
Netherlands336
08

Study locations

26 sites
  • Banner University Medical Center Tucson
    Tucson, Arizona 85724-5030, United States
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • David Geffen School of Medicine at University of California Los Angeles
    Los Angeles, California 90095, United States
  • Rady Children's Hospital San Diego
    San Diego, California 92123, United States
  • University of California San Francisco
    San Francisco, California 94158, United States
  • Stanford University School of Medicine
    Stanford, California 94305, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Children's National Health Center
    Washington D.C., District of Columbia 20010, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30329, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Comer Children's Hospital
    Chicago, Illinois 60637, United States
  • Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21205, United States
  • Boston Childrens' Hospital
    Boston, Massachusetts 02115, United States
  • University of Michigan - Allergy Specialty Clinic and Food Allergy Clinic
    Ann Arbor, Michigan 48106, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • The University of North Carolina - Chapell Hill
    Chapel Hill, North Carolina 27599, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Le Bonheur Children's Hospital
    Memphis, Tennessee 38105, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37204, United States
  • Dell Children's Medical Center of Central Texas
    Austin, Texas 78723, United States
  • Children's Medical Center Dallas
    Dallas, Texas 75235, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Seattle Allergy & Asthma Research Institute
    Seattle, Washington 98115, United States
09

References and documents

Publications

  • Greenhawt M, Albright D, Anvari S, Arends N, Arkwright PD, Begin P, Blumchen K, Brown-Whitehorn T, Cassell H, Chan ES, Ciaccio CE, Deschildre A, Divaret-Chauveau A, Dorris S, Dorsey M, Du Toit G, Eiwegger T, Erlewyn-Lajeunesse M, Fleischer DM, Ford LS, Garcia-Lloret M, O'B Hourihane J, Jay N, Jones SM, Kim EH, Kloepfer K, Leonard S, Lezmi G, Lieberman J, Lomas J, Makhija M, O'Sullivan M, Parrish C, Peake J, Perrett KP, Petroni D, Pongracic JA, Quinn P, Robison RG, Sanders G, Schneider L, Sharma H, Sindher SB, Trujillo J, Turner PJ, Tuttle K, Upton J, Varshney P, Vickery BP, Vogelberg C, Wainstein B, Wang J, Wood R, Bee KJ, Campbell DE, Green TD, Rouissi R, Bahnson HT, Bois T, Sampson HA, Burks AW. Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE. J Allergy Clin Immunol Pract. 2025 May;13(5):1176-1187.e7. doi: 10.1016/j.jaip.2025.02.004. Epub 2025 Feb 14. PubMed 39956162 ↗
  • Greenhawt M, Sindher SB, Wang J, O'Sullivan M, du Toit G, Kim EH, Albright D, Anvari S, Arends N, Arkwright PD, Begin P, Blumchen K, Bourrier T, Brown-Whitehorn T, Cassell H, Chan ES, Ciaccio CE, Deschildre A, Divaret-Chauveau A, Dorris SL, Dorsey MJ, Eiwegger T, Erlewyn-Lajeunesse M, Fleischer DM, Ford LS, Garcia-Lloret M, Giovannini-Chami L, Hourihane JO, Jay N, Jones SM, Kerns LA, Kloepfer KM, Leonard S, Lezmi G, Lieberman JA, Lomas J, Makhija M, Parrish C, Peake J, Perrett KP, Petroni D, Pfutzner W, Pongracic JA, Quinn P, Robison RG, Sanders G, Schneider L, Sharma HP, Trujillo J, Turner PJ, Tuttle K, Upton JE, Varshney P, Vickery BP, Vogelberg C, Wainstein B, Wood RA, Bee KJ, Campbell DE, Green TD, Rouissi R, Peillon A, Bahnson HT, Bois T, Sampson HA, Burks AW. Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy. N Engl J Med. 2023 May 11;388(19):1755-1766. doi: 10.1056/NEJMoa2212895. PubMed 37163622 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in May 2025, 77 months.

Results were first posted in Oct 2026, 1 year 5 months after primary completion.

Of 15 phase 3 interventional studies under Peanut Hypersensitivity, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 42. This study's 77 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2019
First posted
Mar 1, 2019
StartActual
Dec 6, 2018
Primary completionActual
May 13, 2025
CompletionActual
May 13, 2025
Results first posted
Oct 28, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 28, 2026
Sites
1 site added, 1 site removed
Show site
  • Children's National Health Center · Washington D.C., United States
Show 1 removed
  • Children's National Health Center · Washington, United States
Oct 28, 2026
Primary outcomes
1 added, 3 removed
What changed in the outcomes
  • AddedPercentage of Participants Who Were Treatment Responders at Months 12, 24, 36 and 48Time frame: Months 12, 24, 36 and 48
  • RemovedProportion of subjects reaching an ED ≥1000 mgTime frame: 12 months
  • RemovedProportion of subjects reaching an ED ≥1000 mgTime frame: 24 months
  • RemovedProportion of subjects reaching an ED ≥1000 mgTime frame: 36 months
Oct 28, 2026
Documents
Publications
2 publications citing this study linked from PubMed, e.g. PubMed 39956162 ↗
Oct 28, 2026
Secondary outcomes
9 added, 1 removed
What changed in the outcomes
  • RemovedAdverse Events (AEs), Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs)Time frame: Throughout the study during 36 months
  • Addedother outcomePercentage of Participants Reaching an ED ≥ 2000 mg Peanut Protein at Months 12, 24, 36 and 48Time frame: Months 12, 24, 36 and 48
  • Addedother outcomePercentage of Participants Who Tolerated ≥ 1000 mg Peanut Protein at Months 12, 24, 36 and 48Time frame: Months 12, 24, 36 and 48
  • Addedother outcomePercentage of Participants Who Tolerated ≥ 2000 mg Peanut Protein at Months 12, 24, 36 and 48Time frame: Months 12, 24, 36 and 48
  • Addedother outcomeTolerated Doses of Peanut Protein at Baseline and Months 12, 24, 36 and 48Time frame: Baseline and Months 12, 24, 36 and 48
  • Addedother outcomeEDs of Peanut Protein at Baseline and Months 12, 24, 36 and 48Time frame: Baseline and Months 12, 24, 36 and 48
  • Addedother outcomeCumulative Reactive Doses (CRD) of Peanut Protein at Baseline and Months 12, 24, 36 and 48Time frame: Baseline and Months 12, 24, 36 and 48
  • Addedother outcomeNumber of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs), and AEs of Special Interest (AESI)Time frame: During 36 months of active treatment
  • Addedother outcomeNumber of Participants Who Experienced SAEs During DBPCFC After Peanut Formula at Months 12, 24, 36 and 48Time frame: Months 12, 24, 36 and 48
  • Addedother outcomePercentage of Participants Reaching an Eliciting Dose (ED) ≥ 1000 mg Peanut Protein at Months 12, 24, 36 and 48Time frame: 12, 24, 36, 48 months
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Results posted
    Publications 2 publications citing this study linked from PubMed, e.g. PubMed 39956162 ↗
    1 site added, 1 site removed
    Show site
    • Children's National Health Center · Washington D.C., United States
    Show 1 removed
    • Children's National Health Center · Washington, United States
    Primary outcomes 1 added, 3 removed
    What changed in the outcomes
    • AddedPercentage of Participants Who Were Treatment Responders at Months 12, 24, 36 and 48Time frame: Months 12, 24, 36 and 48
    • RemovedProportion of subjects reaching an ED ≥1000 mgTime frame: 12 months
    • RemovedProportion of subjects reaching an ED ≥1000 mgTime frame: 24 months
    • RemovedProportion of subjects reaching an ED ≥1000 mgTime frame: 36 months
    Secondary outcomes 9 added, 1 removed
    What changed in the outcomes
    • RemovedAdverse Events (AEs), Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs)Time frame: Throughout the study during 36 months
    • Addedother outcomePercentage of Participants Reaching an ED ≥ 2000 mg Peanut Protein at Months 12, 24, 36 and 48Time frame: Months 12, 24, 36 and 48
    • Addedother outcomePercentage of Participants Who Tolerated ≥ 1000 mg Peanut Protein at Months 12, 24, 36 and 48Time frame: Months 12, 24, 36 and 48
    • Addedother outcomePercentage of Participants Who Tolerated ≥ 2000 mg Peanut Protein at Months 12, 24, 36 and 48Time frame: Months 12, 24, 36 and 48
    • Addedother outcomeTolerated Doses of Peanut Protein at Baseline and Months 12, 24, 36 and 48Time frame: Baseline and Months 12, 24, 36 and 48
    • Addedother outcomeEDs of Peanut Protein at Baseline and Months 12, 24, 36 and 48Time frame: Baseline and Months 12, 24, 36 and 48
    • Addedother outcomeCumulative Reactive Doses (CRD) of Peanut Protein at Baseline and Months 12, 24, 36 and 48Time frame: Baseline and Months 12, 24, 36 and 48
    • Addedother outcomeNumber of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs), and AEs of Special Interest (AESI)Time frame: During 36 months of active treatment
    • Addedother outcomeNumber of Participants Who Experienced SAEs During DBPCFC After Peanut Formula at Months 12, 24, 36 and 48Time frame: Months 12, 24, 36 and 48
    • Addedother outcomePercentage of Participants Reaching an Eliciting Dose (ED) ≥ 1000 mg Peanut Protein at Months 12, 24, 36 and 48Time frame: 12, 24, 36, 48 months
    + 3 other changes: verification date, arm descriptions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03859700
Lead sponsor
DBV Technologies
Responsible party
Sponsor
First posted
Mar 1, 2019
Start date
Dec 6, 2018
Primary completion
May 13, 2025
Completion
May 13, 2025
Results posted
Oct 28, 2026
Last update
Oct 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palforzia

Start the discussion